Abbott Q3 2020 Earnings Report
Key Takeaways
Abbott announced strong Q3 2020 financial results, driven by innovation and delivery despite challenging conditions. The company's new product pipeline remained highly productive, positioning it well to finish the year with momentum.
Worldwide sales increased 9.6 percent on a reported basis and 10.6 percent on an organic basis.
Worldwide Nutrition sales increased 2.6 percent on a reported basis and 4.1 percent on an organic basis.
Worldwide Diagnostics sales increased 38.2 percent on a reported basis and increased 38.8 percent on an organic basis, with $881 million in global COVID-19 testing-related sales.
Worldwide Medical Devices sales increased 3.4 percent on a reported basis and increased 2.6 percent on an organic basis.
Abbott
Abbott
Forward Guidance
Abbott projects full-year 2020 diluted earnings per share from continuing operations under GAAP of at least $2.35. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $3.55 for full-year 2020.